Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases

Next Previous
X
Search
Trial Profile

Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Bacteraemia; Bacterial infections; Bacterial meningitis; Infectious arthritis; Osteomyelitis; Primary immunodeficiency diseases; Sepsis
  • Focus First in man; Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Octapharma

    • Most Recent Events

    • 15 Dec 2022 Results of two studies (SCGAM-01 & SCGAM-03) assessing efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% in the treatment of patients with primary immunodeficiencies, published in the Clinical and Experimental Immunology.
    • 03 Sep 2020 Status changed from active, no longer recruiting to completed.
    • 27 Aug 2019 Planned End Date changed from 1 Dec 2019 to 1 Jul 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top